# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

> **NCT02140320** · PHASE1 · COMPLETED · sponsor: **Respivert Ltd** · enrollment: 49 (actual)

## Conditions studied

- Asthma
- Healthy Volunteers

## Interventions

- **DRUG:** RV1729 single dose
- **DRUG:** RV1729 matching placebo single dose
- **DRUG:** RV1729 14 day repeat dose
- **DRUG:** RV1729 matching placebo 14 day repeat dose
- **DRUG:** RV1729 28 day repeat dose
- **DRUG:** RV1729 matching placebo 28 day repeat dose

## Key facts

- **NCT ID:** NCT02140320
- **Lead sponsor:** Respivert Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140320, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02140320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*